Monoclonal antibodies in breast cancer: A critical appraisal. (March 2023)

• Record Type: Journal Article
• Authors: Behl, Akanksha; Wani, Zahoor A.; Das, Nagendra Nath; Parmar, Virinder S.; Len, Christophe; Malhotra, Shashwat; Chhillar, Anil K.
• Is Part Of: Critical reviews in oncology/hematology. Volume 183(2023)
• Publication Date: 2023-03
• Subjects: ADCs Antibody Dependent Cells -- CD19 Cluster of Differentiation 19 (antigen) -- MUC28z a chimeric antigen receptor -- FDA federal drug administration -- IL-6 Interleukin 6 -- IL-8- Interleukin 8 -- NCT0 US-FDA clinical trial.gov number affix -- PASylation PASylation technology is a novel method to enhance the pharmacokinetic (PK) properties of biopharmaceuticals -- PEG polyethylene glycol -- PEGylation A biological alternative to PASylation -- mAbs Monoclonal antibodies -- T-DM1 it contains a monoclonal antibody called trastuzumab that binds with HER2 -- IFN-γ Interferon-gamma -- TNBC Triple Negative Breast Cancer; Breast cancer -- MAbs -- Antigen specificity -- Clinical trial -- Precision medicine -- Biobetters; Oncology -- Periodicals; Hematology -- Periodicals; 616.994
• DOI: 10.1016/j.critrevonc.2023.103915
• Languages: English
• ISSNs: 1040-8428

Abstract

Abstract: In breast cancer, mAbs can play multifunctional roles like targeting cancer cells, sometimes directly attacking them, helping in locating and delivering therapeutic drugs to targets, inhibiting cell growth and blocking immune system inhibitors, etc. Monoclonal antibodies are also one of the important successful treatment strategies especially against HER2 but they have not been explored much for other types of breast cancers especially in triple negative breast cancers. Monoclonal antibodies impact the feasibility of antigen specificity, bispecific and trispecific mAbs have opened new doors for more targeted specific efficacy. Monoclonal antibodies can be used diversly and with efficacy as compared to other methods of treatment thus maining it a suitable candidate for breast cancer treatment. However, mAbs treatment also causes various side effects such as fever, trembling, fatigue, headache and muscle pain, nausea/vomiting, difficulty in breathing, rashes and bleeding. Understanding the pros and cons of this strategy, we have explored in this review, the current and future potential capabilities of monoclonal antibodies with respect to diagnosis and treatment of breast cancer. Data availability: Not applicable Graphical Abstract: ga1 Highlights: Multifunctional role of mAbs. mAbs interaction with breast cancer cells. With many prosmAbs have some adverse effects.